🚧 構築中 — データが不正確な場合があります。企業や指標を随時追加しています。
Bristol-Myers Squibb Company logo

Bristol-Myers Squibb Company

BMY•順位 #132•ヘルスケア•製薬 - 総合

時価総額

$125.6B

世界順位

#132

過去最高値

$139.1B

2026-09-03

総成長率

+0%

2026年以降

Market Cap Context

Bristol-Myers Squibb Company Financial Breakdown (FY 2025)

Source: Yahoo Finance — BMY annual filings (2025) →

$48.2B revenue · $13.7B operating income · $7.1B net income

  • ●Operating margin: 28.5% on $48.2B in revenue.
  • ●R&D is 20.6% of revenue ($10.0B).
  • ●Net income margin: 14.6% — $7.1B in profit.
  • ●Free cash flow: $12.8B (26.7% of revenue).

Cost / Operating Expenses

Total operating expenses $34.5B

Total

$31.2B

Cost of revenue· Product / service delivery costs (COGS)$13.9B44.7%
Research & development$10.0B31.9%
Selling, general & administrative· Sales, marketing, and corporate overhead$7.3B23.3%

Capital Expenditures

$1.3B

This fiscal year (near-total AI infrastructure buildout)

Free Cash Flow

$12.8B

Trailing twelve months

Figures rounded from the annual SEC filing. Unaudited. For informational purposes only, not investment advice.

Bristol-Myers Squibb Companyについて

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.

Bristol-Myers Squibb Companyの時価総額推移 (2026–2026)

Bristol-Myers Squibb Company vs Sector Peers by Market Cap

Intuitive Surgical, Inc.ISRG
$159.8B
Vertex Pharmaceuticals IncorporatedVRTX
$132.8B
Novo Nordisk A/SNOVO-B.CO
$125.9B
Bristol-Myers Squibb CompanyBMY
$125.6B
Stryker CorporationSYK
$117.8B
HCA Healthcare, Inc.HCA
$101.5B
SanofiSAN.PA
$95.9B
Elevance Health, Inc.ELV
$95.4B

Bristol-Myers Squibb Companyを比較

順位の推移

年時価総額順位前年比
2026$125.6B#132(↑7)+16.6%
2025$107.8B#139(↓15)+0.1%
2024$107.6B#124(↓3)+15.8%
2023$92.9B#121(↓53)-26.1%
2022$125.8B#68(↑26)+19.0%
2021$105.8B#94(↓13)+3.7%
2020$102.0B#81(↓14)-0.4%
2019$102.4B#67(↓6)+27.7%
2018$80.2B#61(↓9)-12.9%
2017$92.0B#52(↓6)+7.7%
2016$85.4B#46(↓17)-13.0%
2015$98.2B#29(↑11)+19.3%
2014$82.3B#40(↑2)+14.2%
2013$72.0B#42(↑16)+68.8%
2012$42.7B#58(↓15)-3.8%
2011$44.4B#43(↑24)+39.4%
2010$31.8B#67+10.1%
2009$28.9B#67(↓14)+15.0%
2008$25.1B#53(↑28)-7.3%
2007$27.1B#81(↓13)+4.8%
2006$25.9B#68(↑4)+19.9%
2005$21.6B#72(↓11)-6.1%
2004$23.0B#61(↓15)-6.3%
2003$24.5B#46(↓3)+29.4%
2002$19.0B#43(↓18)-53.0%
2001$40.3B#25(↓4)-26.2%
2000$54.6B#21(↑4)+17.1%
1999$46.6B#25(↓8)-2.8%
1998$48.0B#17(↑2)+43.6%
1997$33.4B#19(↑9)+77.5%
1996$18.8B#28(↓2)+31.2%
1995$14.3B#26(↓1)+55.2%
1994$9.2B#25

その他のヘルスケア企業

よくある質問

What is Bristol-Myers Squibb Company's market cap?

Bristol-Myers Squibb Company (BMY) has a market capitalization of $125.6B, making it the #132 largest company in the world by market cap.

What was Bristol-Myers Squibb Company's highest market cap?

Bristol-Myers Squibb Company's all-time high market cap was $139.1B, reached in 2026-09-03. Its highest rank was #68 in 2022.

What sector is Bristol-Myers Squibb Company in?

Bristol-Myers Squibb Company is in the Healthcare sector, specifically the Drug Manufacturers - General industry. It is based in United States.

How has Bristol-Myers Squibb Company's market cap changed over time?

Bristol-Myers Squibb Company has been tracked since 2026. Its market cap has grown by 0% from $125.6B in 2026 to $125.6B today.